Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 95 mmHg and \< 110 mmHg at Visits 1 and 2~* Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 2~* All patients must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 5 (randomization)~Exclusion Criteria:~* Severe hypertension~* Pregnant or nursing (lactating) women~* Pre-menopausal women not taking accepted form of birth control~* Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1~* History of cardiovascular conditions~* Uncontrolled Type 1 or Type 2 diabetes mellitus~* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amlodipine 10 mg (Type: EXPERIMENTAL): Amlodipine 10 mg
- Aliskiren/Amlodipine 150/10 mg (Type: EXPERIMENTAL): Aliskiren/Amlodipine 150/10 mg
- Aliskiren/Amlodipine 300/10 mg (Type: EXPERIMENTAL): Aliskiren/Amlodipine 300/10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).